Antimicrobial Stewardship

S. Ameen, C. NicFhogartaigh
{"title":"Antimicrobial Stewardship","authors":"S. Ameen, C. NicFhogartaigh","doi":"10.1093/oso/9780198801740.003.0028","DOIUrl":null,"url":null,"abstract":"Antimicrobial stewardship (AMS) is a healthcare- system- wide approach to promoting and monitoring the judicious use of antimicrobials (including antibiotics) to preserve their future effectiveness and optimize outcomes for patients. Put simply, it is using the right antibiotic, at the right dose, via the right route, at the right time, for the right duration (Centres for Disease Control, 2010). Antimicrobial resistance (AMR) is a serious and growing global public health concern. Antibiotics are a unique class of drug as their use in individual patients may have an impact on others through the spread of resistant organisms. Antibiotics are essential for saving lives in conditions such as sepsis, and without effective antibiotics even minor operations could be life-threatening due to the risk of resistant infections. Across Europe approximately 25,000 people die each year as a result of hospital infections caused by resistant bacteria, and others have more prolonged and complicated illness. By 2050, AMR is predicted to be one of the major causes of death worldwide. Protecting the use of currently available antibiotics is crucial as discovery of new antimicrobials has stalled. Studies consistently demonstrate that 30–50% of antimicrobial prescriptions are unnecessary or inappropriate. Figure 18.1 shows some of the reasons behind this. As well as driving increasing resistance, unnecessary prescribing leads to unwanted adverse effects, including avoidable drug reactions and interactions, Clostridium difficile-associated diarrhoea, and healthcare-associated infections with resistant micro-organisms, all of which are associated with adverse clinical outcomes, including increased length of hospital stay and mortality, with increased cost to healthcare systems. Prudent use of antibiotics improves patient care and clinical outcomes, reduces the spread of antimicrobial resistance, and saves money. There are a number of global and national guidelines outlining what a robust AMS programme should consist of (see Further reading and useful resources), including: ● Infectious Diseases Society of America (IDSA): Guidelines for Developing an Institutional Programme to Enhance Antimicrobial Stewardship. ● National Institute for Health and Care Excellence (NICE): Antimicrobial Stewardship: Systems and Processes for Effective Antimicrobial Medicine Use [NG15]. ● Department of Health (DoH): Start Smart Then Focus, updated 2015. ● DoH: UK 5- Year Antimicrobial Resistance Strategy 2013 to 2018.","PeriodicalId":274779,"journal":{"name":"Tutorial Topics in Infection for the Combined Infection Training Programme","volume":"612 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2019-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tutorial Topics in Infection for the Combined Infection Training Programme","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/oso/9780198801740.003.0028","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Antimicrobial stewardship (AMS) is a healthcare- system- wide approach to promoting and monitoring the judicious use of antimicrobials (including antibiotics) to preserve their future effectiveness and optimize outcomes for patients. Put simply, it is using the right antibiotic, at the right dose, via the right route, at the right time, for the right duration (Centres for Disease Control, 2010). Antimicrobial resistance (AMR) is a serious and growing global public health concern. Antibiotics are a unique class of drug as their use in individual patients may have an impact on others through the spread of resistant organisms. Antibiotics are essential for saving lives in conditions such as sepsis, and without effective antibiotics even minor operations could be life-threatening due to the risk of resistant infections. Across Europe approximately 25,000 people die each year as a result of hospital infections caused by resistant bacteria, and others have more prolonged and complicated illness. By 2050, AMR is predicted to be one of the major causes of death worldwide. Protecting the use of currently available antibiotics is crucial as discovery of new antimicrobials has stalled. Studies consistently demonstrate that 30–50% of antimicrobial prescriptions are unnecessary or inappropriate. Figure 18.1 shows some of the reasons behind this. As well as driving increasing resistance, unnecessary prescribing leads to unwanted adverse effects, including avoidable drug reactions and interactions, Clostridium difficile-associated diarrhoea, and healthcare-associated infections with resistant micro-organisms, all of which are associated with adverse clinical outcomes, including increased length of hospital stay and mortality, with increased cost to healthcare systems. Prudent use of antibiotics improves patient care and clinical outcomes, reduces the spread of antimicrobial resistance, and saves money. There are a number of global and national guidelines outlining what a robust AMS programme should consist of (see Further reading and useful resources), including: ● Infectious Diseases Society of America (IDSA): Guidelines for Developing an Institutional Programme to Enhance Antimicrobial Stewardship. ● National Institute for Health and Care Excellence (NICE): Antimicrobial Stewardship: Systems and Processes for Effective Antimicrobial Medicine Use [NG15]. ● Department of Health (DoH): Start Smart Then Focus, updated 2015. ● DoH: UK 5- Year Antimicrobial Resistance Strategy 2013 to 2018.
抗菌药物管理
抗菌药物管理(AMS)是一种卫生保健系统范围内的方法,旨在促进和监测抗菌药物(包括抗生素)的明智使用,以保持其未来的有效性并优化患者的预后。简而言之,就是在正确的时间、通过正确的途径、以正确的剂量、在正确的时间使用正确的抗生素(疾病控制中心,2010年)。抗菌素耐药性(AMR)是一个日益严重的全球公共卫生问题。抗生素是一类独特的药物,因为它们在个别患者中的使用可能通过耐药生物的传播对其他人产生影响。抗生素对于挽救败血症等疾病的生命至关重要,如果没有有效的抗生素,即使是小手术也可能因耐药感染的风险而危及生命。在整个欧洲,每年约有2.5万人死于耐药细菌引起的医院感染,还有一些人的病情更为长期和复杂。预计到2050年,抗菌素耐药性将成为全球死亡的主要原因之一。保护现有抗生素的使用至关重要,因为新的抗菌素的发现已经停滞。研究一致表明,30-50%的抗菌药物处方是不必要或不适当的。图18.1显示了背后的一些原因。除了推动耐药性增加外,不必要的处方还会导致不必要的不良反应,包括可避免的药物反应和相互作用、艰难梭菌相关腹泻以及耐药微生物引起的卫生保健相关感染,所有这些都与不良临床结果相关,包括住院时间和死亡率增加,并增加卫生保健系统的成本。谨慎使用抗生素可改善患者护理和临床结果,减少抗菌素耐药性的传播,并节省资金。有一些全球和国家指南概述了一个强大的辅助医疗方案应该包括什么(见进一步阅读和有用的资源),包括:●美国传染病学会(IDSA):制定加强抗菌剂管理的机构方案指南。●国家健康与护理卓越研究所(NICE):抗菌药物管理:有效抗菌药物使用的系统和流程[NG15]。●卫生部(DoH): Smart Start Then Focus, 2015年更新。●DoH:英国2013 - 2018年抗微生物药物耐药性5年战略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信